Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of L1-CAM protein. The antibodies of the present technology are useful in methods for detecting and treating a L1-CAM-positive cancer in a subject in need thereof.

Abstract: Disclosed is a method of spraying a surface with a set-delayed cement. The method comprises providing a set-delayed cement composition comprising water, pumice, hydrated lime, and a set retarder; spraying a surface with the set-delayed cement composition; and allowing the set-delayed cement composition to set on the surface.

Abstract: The fabrication and characterization of large scale inverted organic solar array fabricated using all-spray process is disclosed. Solar illumination has been demonstrated to improve transparent solar photovoltaic devices. The technology using SAM has potential to revolute current silicon-based photovoltaic technology by providing a complete solution processable manufacturing process. The semi-transparent property of the solar module allows for applications on windows and windshields. The inventive arrays are more efficient than silicon solar cells in artificial light environments, permitting use of the arrays in powering microelectromechanical systems and in integration with microelectromechanical systems.

Abstract: In some embodiments, an apparatus includes a memory, storing processor-executable instructions, blacklist terms, and credential dump records, and a processor. The processor receives repository data from targeted remote repositories and stores the repository data as a potential credential dump in the memory when the repository data includes a credential dump attribute. The processor stores the potential credential dump as a probable credential dump when the potential credential dump does not include a blacklist term, in which case the processor also detects a format and delimiter of the probable credential dump. Based on the format and delimiter, pairs of usernames and associated passwords are identified and hashed. If a percentage of the hashes not associated with the credential dump records exceeds a predetermined threshold, the probable credential dump is deemed authentic.

Abstract: Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.

Abstract: Antibody-drug-conjugates (ADC) are provided having a structure of: wherein L is PR3 ligand. The ADC has n drug moieties bound to the Trastuzumab antibody such that the ADC has a drug-to-antibody ratio (DAR) between 2 and 4 and the drug moieties are bound to the Trastuzumab antibody through cysteine (S) or lystine (Lys) residues. The disclosed ADCs are particularly useful in treating breast cancer.

Abstract: The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.

Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein.

Abstract: The present disclosure is directed to compounds (I?) and to their use in methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds (I?) and their use in methods for the treatment of hypertension. The present disclosure is also directed to compounds (I?) and to their use in methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.

Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

Abstract: Disclosed herein is a method of cementing a surface with a set-delayed cement composition. The method comprises providing a set-delayed cement composition comprising water, pumice, hydrated lime, and a set retarder. The method further comprises placing the set-delayed cement composition into or onto a surface to be cemented and allowing the set-delayed cement composition to set in the surface.

Abstract: Disclosed is a method of forming a set cement shape. The method comprises providing a set-delayed cement composition comprising water, pumice, hydrated lime, and a set retarder; forming the set-delayed cement composition into a shape; and allowing the shaped set-delayed cement composition to set.

Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

Abstract: A thin film and a method of making a thin film. The thin film comprises a patterned substrate, a smooth film of electric field tuned quantum dots solution positioned on the patterned substrate, and a thin layer of metal positioned on the thin film. The method begins by drop-casting a quantum dots solution onto a patterned substrate to create a thin film. While the quantum dots solution is drying, a linearly increasing electric filed is applied. The thin film is then placed in a deposition chamber and a thin layer of metal is deposited onto the thin film. Also included are a method of measuring the photoinduced charge transfer (PCT) rate in a quantum dot nanocomposite film and methods of forming a Shottky barrier on a transparent ITO electrode of a quantum dot film.

Abstract: The real-time cyber threat indicator verification mechanism technology (hereinafter “TIVM”) instantiates one or more virtual client emulators to access a source of a threat, in response to a received threat indicator, so as to evaluate validity and/or severity of the potential threat. In one embodiment, the TIVM may receive a cyber threat indicator having identifying information of a cyber threat source; instantiate, in response to the cyber threat indicator, a virtual client emulator; send a control message to cause the virtual client emulator to interact with the cyber threat source based on the identifying information; obtain a confidence indicator relating to the cyber threat indicator based on interaction between the virtual client emulator and the cyber threat source; and generate a cyber threat indicator confirmation report including the confidence indicator.

Abstract: Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.

Abstract: In some embodiments, an apparatus includes a memory, storing processor-executable instructions, blacklist terms, and credential dump records, and a processor. The processor receives repository data from targeted remote repositories and stores the repository data as a potential credential dump in the memory when the repository data includes a credential dump attribute. The processor stores the potential credential dump as a probable credential dump when the potential credential dump does not include a blacklist term, in which case the processor also detects a format and delimiter of the probable credential dump. Based on the format and delimiter, pairs of usernames and associated passwords are identified and hashed. If a percentage of the hashes not associated with the credential dump records exceeds a predetermined threshold, the probable credential dump is deemed authentic.